

Bill Summary
1st Session of the 58th Legislature

Bill No.:	SB 57
Version:	HASB
Request No.:	
Author:	Sen. Rader
Date:	04/27/2021

Bill Analysis

SB 57 authorizes members of the Opioid Overdose Fatality Review Board to access information collected at the central repository under the Anti-Drug Diversion Act. The measure also adds a reference to a definition for the term “opioid use disorder” as used in the opioid prescription limit law. The measure also clarifies exemptions for hospice care and palliative care, and removes the requirement that a patient be in active treatment for cancer to be exempted. The measure removes language allowing the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control to provide unsolicited notification to the licensing board if a pharmacist or practitioner has exhibited prescriptive behavior consistent with generally recognized standards indicating potentially problematic prescribing patterns. Additionally, the measure specifies that opioid use disorder is to be defined by the American Psychiatric Association and clarifies exemptions for patients receiving cancer or aftercare cancer treatment or palliative care in conjunction with a serious illness.

House Amendments

HA’s to the measure provide that nothing in the Anti-Drug Diversion Act shall be construed to require a practitioner to limit or forcibly taper a patient on opioid therapy. Additionally, HA’s provide clarifying language.

Prepared by: Kalen Taylor